Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies

Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies

Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to have high plasma protein binding in human and animal plasma,...

Full description

Bibliographic Details
Main Authors: Jiawang Liu, Nirmal Rajasekaran, Ahamed Hossain, Changde Zhang, Shanchun Guo, Borui Kang, Hunsoon Jung, Hongjoong Kim, Guangdi Wang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
selective estrogen receptor degrader
ZB716
pharmacokinetics
oral bioavailability
breast cancer
fulvestrant
Online Access:https://www.mdpi.com/1424-8247/14/8/719

Internet

https://www.mdpi.com/1424-8247/14/8/719

Similar Items